BioSpace News Archive

Atlas Venture raised $450 million at the close of its thirteenth fundraising activity to support efforts to create and invest in new biotech firms that address many unmet patient needs.

Rising prevalence of chronic and acute diseases worldwide and growing use of biomarkers in drug discovery and development are among the key factors driving the global market revenue growth.

Growing awareness of rare diseases and high incidence rate of psoriasis among children and infants are among the key factors driving the global market revenue growth.

Increasing investments by public and private organizations to develop advanced femtech devices, rising penetration of internet and smartphones and increasing health problems in pregnant women are key some key factors expected to drive global market revenue growth

High preference for non-invasive procedures, rising demand for diagnosis of cancer, increasing investments in research and development activities, and improving healthcare infrastructure are some key factors expected to fuel market revenue growth.

Rising prevalence of pulmonary valvular heart diseases, increasing geriatric population and increasing healthcare expenditure are some key factors expected to drive global market revenue growth.

Chromatography is a method for separating the components or solutes of a mixture and is used in various application areas including biotechnology, pharmaceutical, food production, genetic engineering, and drug discovery among many others.

As of March 1, 2022, the Company has agreed to terminate 100% of its interest in Swiss Stem Cells Biotech, SA, (SSCB). As of March 1, 2022, the Company has agreed to terminate 100% of its interest Re-You Suisse SA.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2021 financial results on Thursday, March 10, 2022, prior to the open of the stock market.

LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates.